Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency (Q39218984)

10 September 2017

title

Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency (English)

1 reference

10 September 2017

8

Mitsune Tanimoto

1 reference

10 September 2017

9

Katsuyuki Kiura

1 reference

10 September 2017

2

Nagio Takigawa

1 reference

10 September 2017

1

Hiromasa Takeda

1 reference

10 September 2017

6

Eiki Ichihara

1 reference

10 September 2017

7

Nobuaki Ochi

1 reference

10 September 2017

3

Kadoaki Ohashi

1 reference

10 September 2017

4

Daisuke Minami

1 reference

10 September 2017

5

Itaru Kataoka

1 reference

10 September 2017

language of work or name

English

0 references

publication date

27 December 2012

1 reference

Experimental Cell Research

10 September 2017

published in

1 reference

10 September 2017

volume

319

1 reference

10 September 2017

issue

4

1 reference

10 September 2017

page(s)

417-423

1 reference

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Tenets of PTEN tumor suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

The BATTLE trial: personalizing therapy for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

RET, ROS1 and ALK fusions in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.12.018

10.1016/J.YEXCR.2012.12.018

7 January 2021

Identifiers

DOI

1 reference

release_ht3kxdkn4ze5zf24k2dy4eylvy

10 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ht3kxdkn4ze5zf24k2dy4eylvy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference